NYSE$ASH
Ashland Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Ashland's financial results for Q2 2023 were reported, with sales consistent with the prior-year quarter. The company updated its fiscal year 2023 financial outlook and announced the completion of a $200 million share repurchase.
Ashland reported sales of $603 million, consistent with the prior-year quarter. Net income was $91 million, and income from continuing operations was $92 million. The company updated its financial outlook for fiscal year 2023, expecting sales in the range of $2.3 billion to $2.4 billion and Adjusted EBITDA in the range of $580 million to $610 million.
- Sales of $603 million were consistent with the prior-year quarter.
- Net income was $91 million, or $1.67 per diluted share.
- Income from continuing operations was $92 million, or $1.68 per diluted share.
- Adjusted EBITDA was $145 million, down 11 percent from the prior-year quarter.
Headline financials
Revenue & EPS history
Ashland · Revenue · Quarterly
$603M
Revenue by segment
Ashland · $619M total across 4 segments · Q2 2023
- Life Sciences$240M+17.6%38.8%
- Personal Care$167M-2.9%27.0%
- Specialty Additives$161M-11.5%26.0%
- Intermediates$51M-22.7%8.2%
Forward guidance
Ashland updated its financial outlook for fiscal year 2023, expecting sales in the range of $2.3 billion to $2.4 billion and Adjusted EBITDA in the range of $580 million to $610 million, reflecting weaker global demand dynamics and inventory-control actions.
Tailwinds
- Demand for pharmaceutical products is expected to remain strong through the second half of the fiscal year.
- Pricing and mix-improvement actions position the company well to cover current cost inflation.
- The company remains confident about the future.
- Customers remain resilient.
- Inventory level was consistent with the level at the close of the December quarter.
Headwinds
- Customer de-stocking is continuing.
- Weaker-than-expected results over the past month and in certain end markets have created greater uncertainty regarding the de-stocking dynamics.
- Inventory destocking creates more uncertainty for Personal Care and Specialty Additives end markets.
- There are increased concerns of further global economic deceleration and the increasing cost of capital.
- Inventory-control actions are expected to negatively impact Adjusted EBITDA in the second half of the fiscal year by approximately $20 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
-0.4%
Avg return
Earnings day
-0.7%
Avg return
5 days after
+0.8%
Avg return
30 days after
45%
29 / 64 earnings
Positive
+15.9%
Q1 2024
Best reaction
-10.2%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | +8.4% | +6.3% | +17.7% | |
| Q1 2026 | -0.8% | +4.2% | -6.8% | |
| Q4 2025 | -1.0% | -1.3% | +15.5% | |
| Q2 2025 | -9.9% | -11.5% | -9.0% | |
| Q1 2025 | -9.8% | -14.4% | -14.5% | |
| Q4 2024 | -5.0% | -7.3% | -11.2% | |
| Q3 2024 | -3.2% | -6.5% | -7.4% | |
| Q2 2024 | -2.6% | -1.2% | +2.7% | |
| Q1 2024 | +15.9% | +13.4% | +15.9% | |
| Q4 2023 | -4.8% | +0.8% | +7.3% | |
| Q3 2023 | +0.1% | +1.3% | -6.9% | |
| Q2 2023 | -10.2% | -9.5% | -15.0% | |
| Q1 2023 | +1.5% | -1.4% | -3.8% | |
| Q4 2022 | +7.9% | +8.0% | +11.9% | |
| Q3 2022 | -2.5% | -4.3% | +1.5% | |
| Q2 2022 | +4.7% | +3.5% | +4.3% | |
| Q1 2022 | +1.2% | -0.8% | -5.9% | |
| Q4 2021 | +1.4% | +7.4% | +5.3% | |
| Q3 2021 | -3.9% | -3.1% | -2.3% | |
| Q2 2021 | -7.0% | -7.3% | +1.2% | |
| Q1 2021 | +1.3% | +2.3% | +3.0% | |
| Q4 2020 | -2.4% | +3.9% | -2.5% | |
| Q3 2020 | -2.5% | -5.2% | -5.1% | |
| Q2 2020 | -0.1% | +5.3% | +20.8% | |
| Q1 2020 | +1.1% | -1.8% | +0.8% | |
| Q4 2019 | -3.8% | -8.6% | -3.8% | |
| Q3 2019 | +0.0% | -3.5% | -8.7% | |
| Q2 2019 | -5.4% | -4.9% | -5.0% | |
| Q1 2019 | +2.7% | +2.0% | +1.8% | |
| Q4 2018 | +9.0% | +8.5% | +2.6% | |
| Q3 2018 | +2.5% | +3.9% | +2.6% | |
| Q2 2018 | +7.7% | +10.6% | +17.4% | |
| Q1 2018 | +0.3% | +2.0% | -2.2% | |
| Q4 2017 | -3.6% | -3.9% | +2.5% | |
| Q3 2017 | -2.4% | -2.3% | -4.5% | |
| Q2 2017 | -1.4% | -2.5% | +7.6% | |
| Q1 2017 | +2.1% | +2.2% | +4.6% | |
| Q4 2016 | -4.1% | -5.3% | +1.3% | |
| Q3 2016 | -6.4% | -6.7% | -4.3% | |
| Q2 2016 | -0.7% | — | — | |
| Q1 2016 | -1.9% | — | — | |
| Q4 2015 | -0.1% | — | — | |
| Q3 2015 | -3.2% | — | — | |
| Q2 2015 | -1.4% | — | — | |
| Q1 2015 | +1.3% | — | — | |
| Q4 2014 | +2.9% | — | — | |
| Q3 2014 | -5.1% | — | — | |
| Q2 2014 | +4.5% | — | — | |
| Q1 2014 | -1.0% | — | — | |
| Q4 2013 | -5.8% | — | — | |
| Q3 2013 | +0.4% | — | — | |
| Q2 2013 | -0.1% | — | — | |
| Q1 2013 | +6.9% | — | — | |
| Q4 2012 | +0.4% | — | — | |
| Q3 2012 | -0.4% | — | — | |
| Q2 2012 | +1.5% | — | — | |
| Q1 2012 | +1.3% | — | — | |
| Q4 2011 | -4.8% | — | — | |
| Q3 2011 | +4.0% | — | — | |
| Q2 2011 | +0.8% | — | — | |
| Q1 2010 | +3.1% | — | — | |
| Q4 2010 | -1.2% | — | — | |
| Q3 2010 | -5.7% | — | — | |
| Q2 2010 | +2.8% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro